SN. logo

Smith & Nephew plc Stock Price

LSE:SN. Community·UK£9.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 71 Fair Values set on narratives written by author

SN. Share Price Performance

UK£11.47
0.40 (3.57%)
UK£14.10
Fair Value
UK£11.47
0.40 (3.57%)
18.6% undervalued intrinsic discount
UK£14.10
Fair Value
Price UK£11.47
AnalystConsensusTarget UK£14.10

SN. Community Narratives

·
Fair Value UK£14.1 18.6% undervalued intrinsic discount

Orthopaedic And Wound Care Advances Will Drive Global Reach And Clinical Outcomes

0users have liked this narrative
0users have commented on this narrative
41users have followed this narrative
UK£14.1
18.6% undervalued intrinsic discount
Revenue
5.94% p.a.
Profit Margin
13.57%
Future PE
19.21x
Price in 2029
UK£18.02

Trending Discussion

Updated Narratives

SN. logo

SN.: Buybacks And New Medical Offerings Will Support Future Upside Potential

Fair Value: UK£14.1 18.6% undervalued intrinsic discount
41 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet and pays a dividend.

1 Risk
6 Rewards

Smith & Nephew plc Key Details

US$6.2b

Revenue

US$2.0b

Cost of Revenue

US$4.2b

Gross Profit

US$3.6b

Other Expenses

US$625.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 04, 2026
0.73
68.25%
10.14%
58.8%
View Full Analysis

About SN.

Founded
1856
Employees
16988
CEO
Deepak Nath
WebsiteView website
www.smith-nephew.com

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Recent SN. News & Updates

Analysis Article May 31

We Ran A Stock Scan For Earnings Growth And Smith & Nephew (LON:SN.) Passed With Ease

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Narrative Update May 11

SN.: Buybacks And New Medical Offerings Will Support Future Upside Potential

Analysts have made a small adjustment to the Smith & Nephew price target to reflect slightly different assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, resulting in a marginal change that keeps the stock’s outlook broadly consistent with prior expectations. What's in the News Announced a new share repurchase program of up to US$500m, to be funded from free cash flow and existing cash balances, with a 12 month duration (Buyback Transaction Announcements).

Recent updates

No updates